A recent review published in the Journal Science Translational Medicine focuses on two new anti-amyloid
antibodies, lecanemab (Eisai and Biogen) and domanemab (Eli Lilly and Co.) that have received FDA approval for early stages of AD and are currently being tested in clinical trials for pre-clinical AD.
The review can be found here: https://www.science.org/doi/10.1126/scitranslmed.adk9993